212 related articles for article (PubMed ID: 38096903)
21. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
22. Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence.
Focosi D; Maggi F; Casadevall A
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215783
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice.
Yang H; Xie Y; Li S; Bao C; Wang J; Li C; Nie J; Quan Y
Hum Vaccin Immunother; 2024 Dec; 20(1):2364519. PubMed ID: 38880868
[TBL] [Abstract][Full Text] [Related]
24. A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques.
He X; Aid M; Chandrashekar A; Yu J; McMahan K; Wegmann F; Jacob-Dolan C; Maron JS; Atyeo C; Wan H; Sellers D; Liu J; Lifton M; Gardner S; Bondzie EA; Barrett J; Ahmad K; Anioke T; Yalley-Ogunro J; Muench J; Goode A; Andersen H; Lewis MG; Alter G; Schuitemaker H; Zahn R; Barouch DH
Sci Transl Med; 2022 Mar; 14(638):eabm4996. PubMed ID: 35191769
[TBL] [Abstract][Full Text] [Related]
25. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
26. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
[TBL] [Abstract][Full Text] [Related]
27. Correlates of protection against SARS-CoV-2 in rhesus macaques.
McMahan K; Yu J; Mercado NB; Loos C; Tostanoski LH; Chandrashekar A; Liu J; Peter L; Atyeo C; Zhu A; Bondzie EA; Dagotto G; Gebre MS; Jacob-Dolan C; Li Z; Nampanya F; Patel S; Pessaint L; Van Ry A; Blade K; Yalley-Ogunro J; Cabus M; Brown R; Cook A; Teow E; Andersen H; Lewis MG; Lauffenburger DA; Alter G; Barouch DH
Nature; 2021 Feb; 590(7847):630-634. PubMed ID: 33276369
[TBL] [Abstract][Full Text] [Related]
28. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.
Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A
PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP.
Solforosi L; Kuipers H; Jongeneelen M; Rosendahl Huber SK; van der Lubbe JEM; Dekking L; Czapska-Casey DN; Izquierdo Gil A; Baert MRM; Drijver J; Vaneman J; van Huizen E; Choi Y; Vreugdenhil J; Kroos S; de Wilde AH; Kourkouta E; Custers J; van der Vlugt R; Veldman D; Huizingh J; Kaszas K; Dalebout TJ; Myeni SK; Kikkert M; Snijder EJ; Barouch DH; Böszörményi KP; Stammes MA; Kondova I; Verschoor EJ; Verstrepen BE; Koopman G; Mooij P; Bogers WMJM; van Heerden M; Muchene L; Tolboom JTBM; Roozendaal R; Brandenburg B; Schuitemaker H; Wegmann F; Zahn RC
J Exp Med; 2021 Jul; 218(7):. PubMed ID: 33909009
[TBL] [Abstract][Full Text] [Related]
31. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
32. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron.
Liu J; Chandrashekar A; Sellers D; Barrett J; Jacob-Dolan C; Lifton M; McMahan K; Sciacca M; VanWyk H; Wu C; Yu J; Collier AY; Barouch DH
Nature; 2022 Mar; 603(7901):493-496. PubMed ID: 35102312
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH
Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529
[TBL] [Abstract][Full Text] [Related]
34. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Ku MW; Bourgine M; Authié P; Lopez J; Nemirov K; Moncoq F; Noirat A; Vesin B; Nevo F; Blanc C; Souque P; Tabbal H; Simon E; Hardy D; Le Dudal M; Guinet F; Fiette L; Mouquet H; Anna F; Martin A; Escriou N; Majlessi L; Charneau P
Cell Host Microbe; 2021 Feb; 29(2):236-249.e6. PubMed ID: 33357418
[TBL] [Abstract][Full Text] [Related]
35. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
37. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
Routhu NK; Cheedarla N; Gangadhara S; Bollimpelli VS; Boddapati AK; Shiferaw A; Rahman SA; Sahoo A; Edara VV; Lai L; Floyd K; Wang S; Fischinger S; Atyeo C; Shin SA; Gumber S; Kirejczyk S; Cohen J; Jean SM; Wood JS; Connor-Stroud F; Stammen RL; Upadhyay AA; Pellegrini K; Montefiori D; Shi PY; Menachery VD; Alter G; Vanderford TH; Bosinger SE; Suthar MS; Amara RR
Immunity; 2021 Mar; 54(3):542-556.e9. PubMed ID: 33631118
[TBL] [Abstract][Full Text] [Related]
38. Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques.
Hasenkrug KJ; Feldmann F; Myers L; Santiago ML; Guo K; Barrett BS; Mickens KL; Carmody A; Okumura A; Rao D; Collins MM; Messer RJ; Lovaglio J; Shaia C; Rosenke R; van Doremalen N; Clancy C; Saturday G; Hanley P; Smith BJ; Meade-White K; Shupert WL; Hawman DW; Feldmann H
mBio; 2021 Aug; 12(4):e0150321. PubMed ID: 34311582
[TBL] [Abstract][Full Text] [Related]
39. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
[TBL] [Abstract][Full Text] [Related]
40. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
